Since there is no evidence of adhering to the REMARK guidelines [22] in the published reports [4, 14, 23], larger studies may be warranted to further evaluate the potential role of AR for enzalutamide therapy in ECs, especially in high grade cancers which only express this receptor. This evidence concerns the gene AR and cancer.